Answers are grounded in this paper and cite their sources.
Refractory Systemic Juvenile Idiopathic Arthritis (SJIA) remains a major source of morbidity and mortality in children with pediatric rheumatic disease [ 1 , 2 ]. Although several potential therapeutic targets have been recently identified, only few patients have been enrolled in ongoing clinical trials. The 4 th “ NextGen Therapies for SJIA and MAS” virtual symposium organized by the “SJIA Foundation” and held February 13–14, 2022 , brought together SJIA families, leading researchers, clinicians and representatives from Pharma and FDA with the main goals to identify barriers to clinical research in this area and develop new strategies to advance it.
No takes yet. Share an insight, caveat, or question.
Sinha et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: